

MARKET REPORT



Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?

Scope

A recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood of generic competition to Teva's multiple sclerosis treatment Copaxone entering the market in May 2014, note analysts, a year earlier than some had anticipated.

Sales of Copaxone are already under threat from oral therapies, most notably Biogen Idec's Tecfidera, so how will a generic version of the drug fare commercially?

Furthermore, Teva hopes to switch up to a third of existing Copaxone patients onto a less frequently dosed version of the drug – three-times weekly versus once daily – but is now potentially faced with a reduced window of opportunity to achieve this before generic versions of the product reach the market.

Current market leader

Copaxone is the current market-leading MS therapy and generated global sales of \$4 billion in 2012 – equal to 27 percent of the market in value terms. Copaxone commanded a 32 percent share of the US market in 2012, based on country-specific sales of \$2.9 billion.

Second-quarter global and US sales of Copaxone crept up sequentially, driven in part by price increases and the impact of patient warehousing for Tecfidera (a recent presentation by Symphony Health Solutions suggested that by its third week of availability, Tecfidera accounted for around 30 percent of all new patient starts in the MS market) - see ViewPoints: Tecfidera streaks towards blockbuster run rate, questions remain over European launch.

The competitive threat from orals

However, of those patients prescribed Tecfidera since launch who have switched from another therapy, around 30 percent have reportedly been migrated from Copaxone. This suggests that over the next year we can expect to see continued uptake of Biogen Idec's drug have a more pronounced negative impact on the performance of Copaxone – a trend that may be enhanced by Tecfidera's favourable comparison to Copaxone in the CONFIRM study.

Teva's efforts to retain market share for the Copaxone franchise are centred on the development of a three-times weekly dosed version of the drug, which would provide added convenience versus the current once-daily version. A supplemental new drug application was accepted by the FDA in April and the company expects a regulatory decision to be made in Q1 2014.

Speaking recently with analysts from Deutsche Bank, Teva management also reiterated its view that erosion to Copaxone should occur at a slower than typical generic rate due in part to the company's patient access programme. Generic challenges do not have the necessary infrastructure to compete in this sense, they argue. Management has previously suggested that they expect to switch around 30 percent of existing Copaxone patients to the new dose.

What about generic Copaxone?

The potential launch of both a new three-times weekly branded Copaxone and cheaper generic Copaxone in 2014 could further shift the dynamics of the MS market, which is currently undergoing notable evolution via the launch of oral products, most notably Tecfidera. Bloomberg Industries analyst Asthika Goonewardene notes suggests that availability of cheaper generic Copaxone may cause some healthcare providers in the US to promote injectable therapies over more expensive oral alternatives.

Purchase Reasons

This week's FirstWord Physician Views poll will ask US-based neurologists:

Whether they believe it ethical to require generic Copaxone to be used as a first-line therapy in relapsing, remitting MS patients?Additional Details

Publisher : FirstWord Pharma

Reference :

Number of Pages : 0

Report Format : PDF

Publisher Information :



FirstWord

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

How to Buy...Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies? [Published by FirstWord Pharma]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/57>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$591** | Single User Price
- \$1186** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.